
Tania Lobo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11272616/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	United States Population-Based Estimates of Patient-Reported Outcomes Measurement Information System Symptom and Functional Status Reference Values for Individuals With Cancer. Journal of Clinical Oncology, 2017, 35, 1913-1920.	1.6	129
2	Responsiveness of 8 Patientâ€Reported Outcomes Measurement Information System (PROMIS) measures in a large, communityâ€based cancer study cohort. Cancer, 2017, 123, 327-335.	4.1	69
3	Behavioral Interventions to Enhance Adherence to Hormone Therapy in Breast Cancer Survivors: AÂSystematic Literature Review. Clinical Breast Cancer, 2016, 16, 247-255.e3.	2.4	55
4	Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1240-1250.	2.5	32
5	Radiation therapy at the end of life: a population-based study examining palliative treatment intensity. Radiation Oncology, 2015, 10, 15.	2.7	26
6	Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1216-1224.	4.9	17
7	A Randomized Trial of Telephone-Based Smoking Cessation Treatment in the Lung Cancer Screening Setting. Journal of the National Cancer Institute, 2022, 114, 1410-1419.	6.3	14
8	The characteristics of patients who quit smoking in the year following a cancer diagnosis. Journal of Cancer Survivorship, 2022, 16, 111-118.	2.9	12
9	Sociodemographic and Clinical Predictors of Switching to Active Treatment among a Large, Ethnically Diverse Cohort of Men with Low Risk Prostate Cancer on Observational Management. Journal of Urology, 2016, 196, 734-740.	0.4	11
10	Study protocol for a telephone-based smoking cessation randomized controlled trial in the lung cancer screening setting: The lung screening, tobacco, and health trial. Contemporary Clinical Trials, 2019, 82, 25-35.	1.8	11
11	Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer. Medical Decision Making, 2019, 39, 962-974.	2.4	10
12	Implementation of the Smoking Treatment and Recovery (STAR) program: healthy cancer survivorship through integrated tobacco control. Journal of Cancer Survivorship, 2020, 14, 53-58.	2.9	10
13	Quality of life among men with low-risk prostate cancer during the first year following diagnosis: the PREPARE prospective cohort study. Translational Behavioral Medicine, 2018, 8, 156-165.	2.4	9
14	Psychological predictors of delayed active treatment following active surveillance for lowâ€risk prostate cancer: The Patient REported outcomes for Prostate cARE prospective cohort study. BJUI Compass, 2022, 3, 226-237.	1.3	4
15	Incidence and Durability of SARS-CoV-2 Antibodies in Patients with Cancer and Health Care Workers following the First Wave of the Pandemic. Journal of Oncology, 2022, 2022, 1-8.	1.3	0